Serial No.: 09/589,777

Page 2

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:

Claim 1 (Cancelled).

2. (Currently amended) An isolated polypeptide comprising the amino acid sequence of which comprises recidues 168-175 and a deletion mutation of an endostatin protein of SEQ ID NO:2, wherein the deletion mutation consists of a deletion of nine consecutive amino acids from the C terminus of the endostatin protein said isolated polypeptide does not contain the amino acid sequence set forth in SEQ ID NO:25, and wherein the isolated polypeptide has anti-angiogenic activity.

Claims 3-10 (Cancelled).

11. (Previously amended) A fusion protein, comprising the isolated polypeptide of Claim 2.

Claims 12 (Cancelled).

- 13. (Previously amended) A composition comprising, as a biologically active ingredient, the polypeptide of Claim 2.
- 14. (Previously amended) The composition of Claim 13, and a pharmaceutically compatible carrier.
- 15. (Original) A composition comprising, as a biologically active ingredient, the fusion protein of Claim 11.

Claims 16-35 (Cancelled).

36. (Currently Allowed) A protein consisting of amino acids 1-175 of SEQ ID NO:2.